
## Bimekizumab Efficacy and Safety in Japanese Patients with Plaque Psoriasis in BE VIVID – a Phase 3, Ustekinumab and Placebo Controlled Study

Akihiko Asahina, Yukari Okubo, Akimichi Morita, Yayoi Tada, Atsuyuki Igarashi, Richard G. Langley, Delphine Deherder, Mizuho Matano, Veerle Vanvoorden, Maggie Wang, Mamitaro Ohtsuki, Hidemi Nakagawa



DLQI 0/1: Dermatology Life Quality Index score of 0 or 1, indicating 'no effect of psoriasis on patient's life'; IGA 0/1: Investigator's Global Assessment score of clear or almost clear with at least two category improvement relative to study start; PASI 90: ≥90% improvement in Psoriasis Area and Severity Index from study start.

**Conclusion:** Bimekizumab resulted in improved clinical response versus ustekinumab and placebo, and was well-tolerated in Japanese patients







The graphical abstract represents the opinions of the authors.

For a full list of declarations, including funding and author disclosure statements, and copyright information, please see the full text online.